TB500
TB-500
A synthetic seven-amino-acid peptide, sequence LKKTETQ, corresponding to the actin-binding region of thymosin beta-4. It is a fragment: thymosin beta-4 itself is a 43-residue protein, and the two are distinct substances that the market frequently treats as one. No receptor target for the fragment has been established in the published literature.
TB-500 has 1 registered human study on ClinicalTrials.gov, reaching phase 2, covering 80 planned or enrolled participants across the 1 study that published a figure. No FDA-approved product contains TB-500. 7 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names TB-500; the registry search is fuzzy, so every match is re-checked. None of this says whether TB-500 works or is safe.
FDA status
Research only
Human studies
1
Furthest phase
Phase 2
Papers, 10 yr
7
Readership
2,321
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
1
Registered human studies
Phase 2
Furthest phase reached
80
Planned or enrolled participants, across 1 study that published a figure
None
No FDA-approved product contains it
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What TB-500 is, and what it has been studied for
TB-500 is tracked here. Its FDA substance identifier is QHK6Z47GTG.
Across 1 registered trial, it has been studied in Atherosclerotic Cardiovascular Diseases and Endothelial Dysfunction. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Hudson Biotech. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
TB-500 reached Phase 2 across 1 registered trial.
No FDA-approved product contains TB-500. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying TB-500?
Papers published each year that name TB-500 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 1 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 0 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 1 | 0 | Yes |
| 2026 | 4 | 1 | No |
7 papers and 1 registered trials between 2017 and 2026. A paper counts when “TB-500” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on TB-500
7 indexed papers name TB-500 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
- Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry
- Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls
- Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5
Collected 2026-08-02from PubMed, phrase-matched on “TB-500” in title and abstract. Run the same search.
About TB-500
A synthetic seven-amino-acid peptide, sequence LKKTETQ, corresponding to the actin-binding region of thymosin beta-4. It is a fragment: thymosin beta-4 itself is a 43-residue protein, and the two are distinct substances that the market frequently treats as one. No receptor target for the fragment has been established in the published literature.
- Also known as
- Thymosin beta-4 fragment 17-23
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.